BREAKING NEWS

BREAKING NEWS

Roche gets European approval for Tecentriq combo vs lung cancer

Roche gets European approval for Tecentriq combo vs lung cancer
FILE PHOTO: Roche tablets are seen in front of a Roche logo in this photo illustration shot January 22, 2016. REUTERS/Dado Ruvic/File Photo -
@ Copyright :
Dado Ruvic(Reuters)
Text size Aa Aa

ZURICH (Reuters) - Roche has received European Commission approval for its Tecentriq drug in combination with Avastin and chemotherapy as an initial treatment for people with a specific type of lung cancer, the Swiss pharma company said on Friday.

The combination has been approved as a first-line treatment for people with metastatic non-squamous non-small cell lung cancer (NSCLC).

NSCLC is the most common type of lung cancer, accounting for about 85 percent of all cases, Roche said.

(Reporting by John Revill, Editing by Tassilo Hummel)

euronews provides breaking news articles from reuters as a service to its readers, but does not edit the articles it publishes. Articles appear on euronews.com for a limited time.